peanut allergy

WASHINGTON: DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down. Nasdaq-listed shares of the French drug developer plunged 60.5 percent to $19 in extended trading. The trial, which tested a 250 microgram stick-on patch called Viaskin Peanut, in 356 children between the ages of 4-11, missed the main goal of achieving a certain tolerance to peanut protein. Shares of rival Aimmune Therapeutics…

MELBOURNE: Australian researchers have reported a major breakthrough in the relief of deadly peanut allergy with the discovery of a long-lasting treatment they say offers hope that a cure will soon be possible. In clinical trials conducted by scientists at Melbourne's Murdoch Childrens Research Institute, children with peanut allergies were given a probiotic along with small doses of a peanut protein over an 18-month period. When the experiment ended in 2013 some 80 percent of the kids were able to tolerate peanuts.…